Statistical analysis plan (SAP) for the Very Early Rehabilitation in Speech (VERSE) after stroke trial

an international 3-arm clinical trial to determine the effectiveness of early, intensive, prescribed, direct aphasia therapy

Erin Godecke, Tapan Rai, Dominique A. Cadilhac, Elizabeth Armstrong, Sandy Middleton, Natalie Ciccone, Anne Whitworth, Miranda L. Rose, Audrey Holland, Fiona Ellery, Graeme J. Hankey, Julie Bernhardt, for the VERSE Collaboration

Research output: Contribution to journalArticleOtherpeer-review

Abstract

Background: Limited evidence exists to support very early intensive aphasia rehabilitation after stroke. VERSE is a PROBE trial designed to determine whether two types of intensive aphasia therapy, beginning within 14 days of acute stroke, provide greater therapeutic and cost-effectiveness than usual care. Objective: To publish the detailed statistical analysis plan for the VERSE trial prior to unblinding. This statistical analysis plan was based on the published and registered VERSE trial protocol and was developed by the blinded steering committee and management team, led by the trial statistician. This plan was developed using outcome measures and trial data collection forms. Results: The VERSE statistical analysis plan is consistent with reporting standards for clinical trials and provides for clear and open reporting. Conclusions: Publication of a statistical analysis plan serves to reduce potential trial reporting bias and outlines transparent pre-specified analyses. Australian New Zealand Clinical Trials Registry (ANZCTR) Registration number: ACTRN12613000776707; Universal Trial Number (UTN) is U1111-1145-4130.

Original languageEnglish
Pages (from-to)863-880
Number of pages18
JournalInternational Journal of Stroke
Volume13
Issue number8
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • Aphasia
  • Randomised controlled trial
  • Statistical analysis plan
  • Stroke Rehabilitation

Cite this

Godecke, Erin ; Rai, Tapan ; Cadilhac, Dominique A. ; Armstrong, Elizabeth ; Middleton, Sandy ; Ciccone, Natalie ; Whitworth, Anne ; Rose, Miranda L. ; Holland, Audrey ; Ellery, Fiona ; Hankey, Graeme J. ; Bernhardt, Julie ; for the VERSE Collaboration. / Statistical analysis plan (SAP) for the Very Early Rehabilitation in Speech (VERSE) after stroke trial : an international 3-arm clinical trial to determine the effectiveness of early, intensive, prescribed, direct aphasia therapy. In: International Journal of Stroke. 2018 ; Vol. 13, No. 8. pp. 863-880.
@article{79d46009bbf94044a6be57343b0a8478,
title = "Statistical analysis plan (SAP) for the Very Early Rehabilitation in Speech (VERSE) after stroke trial: an international 3-arm clinical trial to determine the effectiveness of early, intensive, prescribed, direct aphasia therapy",
abstract = "Background: Limited evidence exists to support very early intensive aphasia rehabilitation after stroke. VERSE is a PROBE trial designed to determine whether two types of intensive aphasia therapy, beginning within 14 days of acute stroke, provide greater therapeutic and cost-effectiveness than usual care. Objective: To publish the detailed statistical analysis plan for the VERSE trial prior to unblinding. This statistical analysis plan was based on the published and registered VERSE trial protocol and was developed by the blinded steering committee and management team, led by the trial statistician. This plan was developed using outcome measures and trial data collection forms. Results: The VERSE statistical analysis plan is consistent with reporting standards for clinical trials and provides for clear and open reporting. Conclusions: Publication of a statistical analysis plan serves to reduce potential trial reporting bias and outlines transparent pre-specified analyses. Australian New Zealand Clinical Trials Registry (ANZCTR) Registration number: ACTRN12613000776707; Universal Trial Number (UTN) is U1111-1145-4130.",
keywords = "Aphasia, Randomised controlled trial, Statistical analysis plan, Stroke Rehabilitation",
author = "Erin Godecke and Tapan Rai and Cadilhac, {Dominique A.} and Elizabeth Armstrong and Sandy Middleton and Natalie Ciccone and Anne Whitworth and Rose, {Miranda L.} and Audrey Holland and Fiona Ellery and Hankey, {Graeme J.} and Julie Bernhardt and {for the VERSE Collaboration}",
year = "2018",
month = "10",
day = "1",
doi = "10.1177/1747493018790055",
language = "English",
volume = "13",
pages = "863--880",
journal = "International Journal of Stroke",
issn = "1747-4930",
publisher = "Wiley-Blackwell",
number = "8",

}

Statistical analysis plan (SAP) for the Very Early Rehabilitation in Speech (VERSE) after stroke trial : an international 3-arm clinical trial to determine the effectiveness of early, intensive, prescribed, direct aphasia therapy. / Godecke, Erin; Rai, Tapan; Cadilhac, Dominique A.; Armstrong, Elizabeth; Middleton, Sandy; Ciccone, Natalie; Whitworth, Anne; Rose, Miranda L.; Holland, Audrey; Ellery, Fiona; Hankey, Graeme J.; Bernhardt, Julie; for the VERSE Collaboration.

In: International Journal of Stroke, Vol. 13, No. 8, 01.10.2018, p. 863-880.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Statistical analysis plan (SAP) for the Very Early Rehabilitation in Speech (VERSE) after stroke trial

T2 - an international 3-arm clinical trial to determine the effectiveness of early, intensive, prescribed, direct aphasia therapy

AU - Godecke, Erin

AU - Rai, Tapan

AU - Cadilhac, Dominique A.

AU - Armstrong, Elizabeth

AU - Middleton, Sandy

AU - Ciccone, Natalie

AU - Whitworth, Anne

AU - Rose, Miranda L.

AU - Holland, Audrey

AU - Ellery, Fiona

AU - Hankey, Graeme J.

AU - Bernhardt, Julie

AU - for the VERSE Collaboration

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background: Limited evidence exists to support very early intensive aphasia rehabilitation after stroke. VERSE is a PROBE trial designed to determine whether two types of intensive aphasia therapy, beginning within 14 days of acute stroke, provide greater therapeutic and cost-effectiveness than usual care. Objective: To publish the detailed statistical analysis plan for the VERSE trial prior to unblinding. This statistical analysis plan was based on the published and registered VERSE trial protocol and was developed by the blinded steering committee and management team, led by the trial statistician. This plan was developed using outcome measures and trial data collection forms. Results: The VERSE statistical analysis plan is consistent with reporting standards for clinical trials and provides for clear and open reporting. Conclusions: Publication of a statistical analysis plan serves to reduce potential trial reporting bias and outlines transparent pre-specified analyses. Australian New Zealand Clinical Trials Registry (ANZCTR) Registration number: ACTRN12613000776707; Universal Trial Number (UTN) is U1111-1145-4130.

AB - Background: Limited evidence exists to support very early intensive aphasia rehabilitation after stroke. VERSE is a PROBE trial designed to determine whether two types of intensive aphasia therapy, beginning within 14 days of acute stroke, provide greater therapeutic and cost-effectiveness than usual care. Objective: To publish the detailed statistical analysis plan for the VERSE trial prior to unblinding. This statistical analysis plan was based on the published and registered VERSE trial protocol and was developed by the blinded steering committee and management team, led by the trial statistician. This plan was developed using outcome measures and trial data collection forms. Results: The VERSE statistical analysis plan is consistent with reporting standards for clinical trials and provides for clear and open reporting. Conclusions: Publication of a statistical analysis plan serves to reduce potential trial reporting bias and outlines transparent pre-specified analyses. Australian New Zealand Clinical Trials Registry (ANZCTR) Registration number: ACTRN12613000776707; Universal Trial Number (UTN) is U1111-1145-4130.

KW - Aphasia

KW - Randomised controlled trial

KW - Statistical analysis plan

KW - Stroke Rehabilitation

UR - http://www.scopus.com/inward/record.url?scp=85055076769&partnerID=8YFLogxK

U2 - 10.1177/1747493018790055

DO - 10.1177/1747493018790055

M3 - Article

VL - 13

SP - 863

EP - 880

JO - International Journal of Stroke

JF - International Journal of Stroke

SN - 1747-4930

IS - 8

ER -